Identification of candidate genes for lung cancer somatic mutation test kits

Genetics and Molecular Biology

Volumn 36, Issue 3, 2013, Pages 455-464

  Chen, Yong ^a   Shi, Jian Xin ^a   Pan, Xu Feng ^a   Feng, Jian ^a   Zhao, Heng ^a  

^a SHANGHAI CHEST HOSPITAL   (China)

Author keywords

COSMIC; Lung cancer; Next generation sequencing; Somatic mutation kit

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN P53;

AKT1 GENE; ANALYTICAL EQUIPMENT; ARTICLE; CANCER SURVIVAL; EGFR GENE; GENE IDENTIFICATION; GENETIC DATABASE; GENOME; HUMAN; LUNG CANCER; MUTATION RATE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PROTEIN PROTEIN INTERACTION; SOMATIC MUTATION; SOMATIC MUTATION TEST KIT; TP53 GENE; TUMOR GENE;

EID: 84883304854     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572013000300022     Document Type: Article

References (27)

1. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal P and Stratton M (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91:355-358.
2. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J and Nicholson A (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997.
3. Dy GK and Adjei AA (2002) Novel targets for lung cancer therapy: Part II. J Clin Oncol 20:3016-3028.
4. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA and Song Y (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356.
5. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K and Menzies A (2011) COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-D950.
6. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237-2246.
7. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, et al. (2004). Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784.
8. Haider S, Ballester B, Smedley D, Zhang J, Rice P and Kasprzyk A (2009) BioMart Central Portal - Unified access to biological data. Nucleic Acids Res 37:W23-W27.
9. Huncharek M, Muscat J and Geschwind JF (1999) K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: A combined analysis of 881 cases. Carcinogenesis 20:1507-1510.
10. Jemal A,Bray F,Center MM,Ferlay J,Ward E andForman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
11. Jemal A, Center MM, DeSantis C and Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907.
12. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA and Jacks T (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111-1116.
13. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158.
14. Liu G, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, Chen Z, Seymour L, Shepherd FA and Tsao MS (2012) Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced nonsmall cell lung cancer. J Thorac Oncol 7:316-322.
15. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ and Bell DW (2008) Detection of mutations in EGFR in circulating lungcancer cells. N Engl J Med 359:366-377.
16. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS and Wistuba II (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896.
17. Mathivanan S, Periaswamy B, Gandhi T, Kandasamy K, Suresh S, Mohmood R, Ramachandra Y and Pandey A (2006) An evaluation of human protein-protein interaction data in the public domain. BMC Bioinformatics 7:S19.
18. Mogi A and Kuwano H (2011) TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol 2011:583929.
19. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
20. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Medicine 2:e17.
21. Perez-Morales R, Mendez-Ramirez I, Castro-Hernandez C, Martinez-Ramirez OC, Gonsebatt ME and Rubio J (2011) Polymorphisms associated with the risk of lung cancer in a healthy Mexican Mestizo population: Application of the additive model for cancer. Genet Mol Biol 34:546-552.
22. Politi K and Lynch TJ (2012) Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. Clin Cancer Res 18:1490-1492.
23. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967.
24. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M and Enoksson J (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554.
25. Sithanandam G, Kolch W, Duh FM and Rapp UR (1990) Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 5:1775-1780.
26. Spigel DR, Burris 3rd HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, et al. (2011) Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-smallcell lung cancer. J Clin Oncol 29:2582-2589.
27. Youlden DR, Cramb SM and Baade PD (2008) The International Epidemiology of Lung Cancer: Geographical distribution and secular trends. J Thorac Oncol 3:819-831.